Business
VAXXA: Insolvency segment up 30% over Q1, with short-term losses from expansion investments
VAXXA: Insolvency segment up 30% over Q1, with short-term losses from expansion investments
About this update from Vaxxa Ab
Revenue and earnings declined year-over-year due to major investments in expansion, but the insolvency segment grew 30% over Q1. Margins are expected to improve as new capacity becomes operational.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.